Clene

CLNN Rare disease Lead: Phase 3 ★ Read the deep dive → 12 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

ACT-EAP corporate updateAug 31, 2026ACT-EAP corporate update, Aug 31, 2026, routine
CNM-Au8 ALS NDA filingearly 4Q 2026CNM-Au8 ALS NDA filing, early 4Q 2026, major
Clene financials corporate updateNov 2026Clene financials corporate update, Nov 2026, routine
RESTORE-ALS Phase 3 Ph3 start2Q 2027RESTORE-ALS Phase 3 Ph3 start, 2Q 2027, routine
2024 SSCP Notes corporate updateAug 13, 20272024 SSCP Notes corporate update, Aug 13, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

CNM-Au8

Small Molecule Target: NAD+, mitochondrial dysfunction

Amyotrophic Lateral Sclerosis Phase 3 oral NCT04098406
Multiple Sclerosis Phase 2 oral NCT03536559
Parkinson's Disease Phase 2 oral

CNM-ZnAg

Small Molecule

Undisclosed indication NCT04610138

CNM-AgZn17

Small Molecule

Undisclosed indication topical

Technology platforms

CSN

Clean-surfaced nanotechnology (CSN) electro-crystal-chemistry platform producing catalytically-active, faceted nanocrystals and ionic solutions from transition elements. Enables development of nanotherapeutics targeting cellular energy impairments in neurodegenerative and other diseases. Flexible and tunable — can produce gold, gold-platinum, and other elemental or composite nanocrystals, plus ionic solutions of silver, zinc, and other transition elements.

Targets: NAD+, mitochondrial dysfunction, reactive oxygen species

electro-crystal-chemistry

Electro-crystal-chemistry drug development platform enabling production of concentrated, stable, highly active, clean-surfaced nanocrystal suspensions; focus on central nervous system disorders including ALS, MS, and Parkinson's disease

Biotech Distilled coverage (12)

2026-08-15 UPDATE: Clene Inc. (CLNN) - A New Name Shows Up on the Cap Table 🔒 Paid
2026-08-12 UPDATE: Clene Inc. (CLNN) - The 14.8% Holder Just Went to Zero 🔒 Paid
2026-08-11 UPDATE: Clene Inc. (CLNN) - Clene Did the FDA’s Homework. The Tape Hasn’t Noticed. 🔒 Paid
2026-05-15 UPDATE: Clene Inc. (CLNN) – The Q1 10-Q Answers Three Questions I Left Open 🔒 Paid
2026-05-05 UPDATE: Clene Inc. (CLNN) - The Raise-Into-Strength Trade, Same Day 🔒 Paid
2026-05-04 UPDATE: Clene Inc. (CLNN) – The Tofersen Precedent Just Landed
2026-03-21 UPDATE: Clene Inc. (CLNN) – The Hidden Catalyst of Non-Dilutive Funding 🔒 Paid
2026-03-14 UPDATE: Clene Inc. (CLNN) – 2025 Earnings Confirm the Dilution Thesis and the Timeline 🔒 Paid
2026-02-28 UPDATE: Clene Inc. (CLNN) – The FDA Showdown Officially Gets a Timeline 🔒 Paid
2026-01-13 UPDATE: Clene Inc. (CLNN) – A Sell the News Moment & The Science Behind It 🔒 Paid
2026-01-12 UPDATE: Clene Inc. (CLNN) – The Dilution Gap Is Effectively Gone for 12-Months. Now It’s Just Science 🔒 Paid
2025-12-30 Clene Inc (CLNN): Scientific Due Diligence for CNM-Au8 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.